The software assists radiologists during reviews of CT colonography (CTC, a.k.a. virtual colonoscopy) images by automatically highlighting potential colorectal polyps, which are possible precursors to colorectal cancer.
Medicsight PLC and Ziosoft Inc., have announced the integration of Medicsight’s ColonCAD API software and Ziosoft’s Ziostation. Ziosoft, based in Redwood City, Calif., will distribute the technologies in the United States under the terms of the deal.
The FDA approved ColonCAD API for clinical use in May. The software assists radiologists during reviews of CT colonography (CTC, a.k.a. virtual colonoscopy) images by automatically highlighting potential colorectal polyps, which are possible precursors to colorectal cancer. The FDA’s green light came after a clinical trial involving 15 radiologist readers who each reviewed 112 patient CT colonography cases. When assisted by ColonCAD, radiologists’ accuracy for detecting polyps of all sizes was significantly improved compared with unassisted reading, Medicsight officials said.
“The partnership between Ziosoft and Medicsight should make a compelling match for CT colonography interpretation,” said Perry J. Pickhardt, professor of Radiology at the University of Wisconsin, one of the first U.S. sites slated to use the combined Medicsight and Ziosoft technologies. “CTC will definitely benefit from the pairing of these companies which are two recognized leaders in the advanced visualization field.”
Ziosoft holds numerous clearances for applications for its supercomputing visualization and functional analytics technology. Medicsight and Ziosoft have been partnering in Europe prior to the U.S. clearance of ColonCAD software.
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Could Ultrafast MRI Enhance Detection of Malignant Foci for Breast Cancer?
April 10th 2025In a new study involving over 120 women, nearly two-thirds of whom had a family history of breast cancer, ultrafast MRI findings revealed a 5 percent increase in malignancy risk for each second increase in the difference between lesion and background parenchymal enhancement (BPE) time to enhancement (TTE).
AMA Approves Category III CPT Codes for AI-Enabled Perivascular Fat Analysis from CT Scans
April 9th 2025Going into effect in 2026, the new CPT codes may facilitate increased adoption of the CaRi-Heart software for detecting coronary inflammation from computed tomography scans pending FDA clearance of the technology.